TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Tue Sep 16

NL

Article

TMFBiologyFool published an article 2:08 PM

5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know

Highlights from Arena Pharmaceuticals' conference call with investors.

Thu Sep 11

NL

Article

TMFBiologyFool published an article 4:35 PM

FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug

Orexigen and Takeda's Contrave has the right balance of efficacy and safety.

Wed Sep 10

NL

Article

TMFBiologyFool published an article 7:08 PM

Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca

Medivation and Astellas get expanded FDA approval for Xtandi with a label that looks better than Johnson & Johnson's Zytiga.

Mon Sep 8

NL

Article

TMFBiologyFool published an article 2:50 PM

3 Reasons MannKind Corporation's Stock Could Fall

MannKind is dependent on the launch of inhaled insulin Afrezza and its marketing partner Sanofi.

Fri Sep 5

NL

Article

TMFBiologyFool published an article 5:46 PM

Ebola Outbreak Strikes Africa: How We're Fighting Back

Multiple drugs and vaccines are in development.

Thu Sep 4

NL

Article

TMFBiologyFool published an article 4:50 PM

Merck & Co., Inc. Wins First Stage of the PD-1 Race

Merck gains FDA approval for Keytruda, but the race isn't over yet.

Wed Sep 3

NL

Article

TMFBiologyFool published an article 4:32 PM

3 Reasons Gilead Sciences, Inc.’s Stock Could Fall

Hepatitis C price wars, its pipeline, and unknown side effects could down Gilead Sciences.

Tue Sep 2

NL

Article

TMFBiologyFool published an article 4:04 PM

5 Things Biogen Idec Inc's Management Wants You to Know

Highlights from Biogen Idec's conference call.

Mon Sep 1

NL

Article

TMFBiologyFool published an article 3:11 PM

Great Cholesterol Drug Data From Regeneron Pharmaceuticals Inc. and Sanofi SA, but Read the Fine Pri

Regeneron Pharmaceuticals and Sanofi's PCSK9 drug, alirocumab, reduces cardiovascular events, but the data come from a post-hoc analysis.

Thu Aug 28

NL

Article

TMFBiologyFool published an article 2:16 PM

Has Gilead Sciences, Inc.'s Star Drug Already Peaked?

Prescriptions of Gilead Sciences' hepatitis C drug Sovaldi peaked, but sales will pick up after the new combination product is approved.

Tue Aug 26

NL

Article

TMFBiologyFool published an article 5:56 PM

7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know

Highlights from Regeneron's conference call.

Mon Aug 25

NL

Article

TMFBiologyFool published an article 3:26 PM

Up 35% on Buyout: InterMune inc Investor Key Takeaways

FDA's rejection of InterMune's Esbriet hurt investors, but Roche clearly thinks the drug will be approved.

Wed Aug 20

NL

Article

TMFBiologyFool published an article 5:09 PM

3 Reasons Gilead Science, Inc.’s Stock Could Rise

Hepatitis C sales, a smart acquisition, and the potential for a dividend could all increase Gilead Sciences' stock price further.

Fri Aug 15

NL

Article

TMFBiologyFool published an article 3:24 PM

A Double Dose of Good News for Gilead Sciences, Inc.

Gilead Sciences gets a lawsuit win over Roche, keeping control of its hepatitis C drug Sovaldi. And the U.K.'s National Institute for Health and Care Excellence agrees to cover Sovaldi.

Wed Aug 13

NL

Article

TMFBiologyFool published an article 7:42 PM

Why Amgen, Inc.’s Kyprolis FOCUS Failure Is a Big Deal

European regulators are going to want to see survival data for Kyprolis.

NL

Article

TMFBiologyFool published an article 4:53 PM

5 Things MannKind Corp.'s Management Wants You to Know

Quotes from MannKind Corp.'s conference calls.

Mon Aug 11

NL

Article

TMFBiologyFool published an article 9:48 PM

Intercept Pharmaceuticals, Inc. Finally Releases FLINT Trial Data

Intercept Pharmaceuticals releases FLINT trial data in NASH patients.

NL

Article

TMFBiologyFool published an article 1:43 PM

MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted

MannKind establishes a partnership with Sanofi to market its inhaled insulin Afrezza.

Fri Aug 8

NL

Article

TMFBiologyFool published an article 3:28 PM

Why Walgreen is Staying American and Paying Its Taxes

Walgreens buys Switzerland-based Alliance Boots, but decides not to move overseas in the process.

Thu Jul 24

NL

Article

TMFBiologyFool published an article 5:01 PM

Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger

Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 95.83
Player Rank 3133 out of 75036
Score 1258.08
Score Change Today -7.39
Accuracy 65.87%
Active Picks 73
Total Picks 213
Best Pick MYL (+247.91)
Worst Pick ITMN (-426.17)
Average Score per Pick 5.91
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts